Primary antibiotic resistance of Helicobacter pylori among a Chinese Tibetan population

Author:

Tang Xiaoqiong1,Chen Xiaohong2,Shen Yalin1,Yang Tiankuo1,Hu Renwei3,Debowski Aleksandra W45ORCID,Stubbs Keith A5ORCID,Benghezal Mohammed1,Marshall Barry J4,Li Hong1ORCID,Tang Hong1ORCID

Affiliation:

1. West China Marshall Research Center for Infectious Diseases, Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, 610041, China

2. Department of Digestive Medicine, Hospital of Chengdu Office of People’s Government of Tibetan Autonomous Region, Chengdu, 610041, China

3. Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, 610041, China

4. Helicobacter pylori Research Laboratory, School of Biomedical Sciences, Marshall Centre for Infectious Disease Research & Training, University of Western Australia, Nedlands, Perth, 6009, Australia

5. School of Molecular Sciences, University of Western Australia, Crawley, Perth, 6009, Australia

Abstract

Aim: To evaluate the primary antibiotic resistance in Helicobacter pylori strains isolated from a Chinese Tibetan population. Methods & materials: Gastric biopsies from 400 H. pylori treatment-naive Tibetan patients were collected for H. pylori isolation. Susceptibility to amoxicillin (AML)/clarithromycin (CLR)/levofloxacin (LEV)/metronidazole (MTZ)/tetracycline (TET)/rifampicin (RIF)/furazolidone (FZD) was determined by E-test or a disk diffusion assay. Results: Biopsies from 117 patients were H. pylori culture positive (29.3%). The primary resistance rates to MTZ, CLR, LEV, RIF, AML, TET and FZD were 90.6, 44.4, 28.2, 69.2, 7.7, 0.8 and 0.8%, respectively. Interestingly, 42.7% of the strains had simultaneous resistance to CLR and MTZ. Conclusion: Among Tibetan strains, primary resistance rates were high for CLR/MTZ/LEV, whereas primary resistance rates to AML/TET/FZD were low. The high resistance to RIF is a concerning finding.

Funder

1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University

National Natural Science Foundation of China

Publisher

Future Medicine Ltd

Subject

Microbiology (medical),Microbiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3